Regulatory expectations for your HCP analysis: meet USP <1132.1> to enhance the quality of MS-based data
Event Overview USP 1132.1 is a newly introduced chapter by the United States Pharmacopeia, effective from May 1, 2025. It outlines best practices for measuring residual host cell proteins (HCPs) in biologics using liquid chromatography–mass spectrometry (LC-MS/MS)....
Opportunities and challenges from ICH Q2 (2) and Q14 for the analytical lifecycle
Join our experts, and by attending this webinar, you will: Gain a clearer understanding of the updates in ICH Q2 (R2) and Q14, as well as the primary challenges these guidelines pose throughout the analytical lifecycle. Explore opportunities to leverage the improved...
Moving HCP LC-MS analysis into a GMP environment
Event Overview Some products, such as advanced therapies and vaccines, are too complex to produce suitable antigens for generating ELISA antibodies for HCP analysis. Moreover, developing process-specific ELISA assays can be very time-consuming and costly....
Advanced ELISA-MS™ for Host Cell Protein (HCP) coverage and ELISA Antibody Characterisation
Event Overview This presentation showcases advanced ELISA-MS™ as the premier technology for detailed characterisation and comprehensive coverage of Host Cell Protein (HCP) ELISA reagents. Precisely assessing HCP coverage is essential for biopharmaceutical development...
Using LIMS to solve key laboratory challenges
[dpddg_dynamic_gallery _builder_version="4.27.4" _module_preset="default" theme_builder_area="post_content" dynamic_content="on" dynamic_content_field="add_image_from_media_registration" show_title="on" show_overlay="on" overlay_action="link"...
Beyond Sample Tracking – LIMS as the Backbone of Laboratory Data Integrity
Event Overview USP 1132.1 is a newly introduced chapter by the United States Pharmacopeia, effective from May 1, 2025. It outlines best practices for measuring residual host cell proteins (HCPs) in biologics using liquid chromatography–mass spectrometry (LC-MS/MS)....
Translating small-molecule development to complex generics and biosimilars
An Overview of Key Differences of the CMC Processes in Small-Molecule Drugs and Biotherapeutics
Advertisement
Advertisement
Advertisement